Clinical characteristics and prognosis analysis of patients with de novo ASXL1‐mutated AML treated with the C‐HUNAN‐AML‐15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 12; pp. 13182 - 13192
• Main Authors: Zeng, Minhui, Chen, Keke, Tian, Xin, Zou, Runying, Feng, Xiaoqin, Li, Chunfu, Li, Jian, Zheng, Mincui, Mai, Huirong, Yang, Lihua, He, Yingyi, Xu, Honggui, Wen, Hong, He, Xiangling
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2023; John Wiley and Sons Inc; Wiley
• Subjects: Acute myeloid leukemia; Adult; AML; ASXL1 mutation; Bone marrow; Chemotherapy; Child; Chromosomes; Cytogenetics; Genes; Hematopoietic stem cells; Humans; Karyotypes; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - therapy; Medical prognosis; Morphology; Multicenter Studies as Topic; Mutation; Nucleophosmin; Patients; Pediatrics; Polymerase chain reaction; Prognosis; Remission Induction; Repressor Proteins - genetics; Software; Stem cell transplantation; Transcription Factors - genetics; transplantation; China; AML; ASXL1 mutation; prognosis; pediatrics; transplantation

Background ASXL1 mutation is an independent prognostic factor in adult acute myeloid leukemia (AML), but its effect on the prognosis of pediatric AML is poorly understood. Aims This study aimed to investigate the clinical characteristics and prognostic factors of ASXL1‐mutant pediatric AML from a la...